Abstract. It has been recognized that sympathetic neurons release several transmitters but mainly adenosine 5'-triphosphate (ATP), noradrenaline, and neuropeptide Y (NPY). Recently, we reported that periarterial nerve electrical stimulation (PNS) produced biphasic vasoconstrictions consisting of an initial transient, predominantly P2X-purinoceptor-mediated constriction followed by a prolonged, a 1 -adrenoceptor-mediated one in canine isolated splenic arteries. In this article, we tried to analyze the effects of several selective key drugs that influence the PNSinduced responses, and we functionally showed sympathetic transmitter releasing mechanisms by pharmacological analysis using purinergic, adrenergic, and NPYergic agonists and antagonists.
Introduction
The peripheral autonomic nervous system is subdivided into the sympathetic and parasympathetic parts. Until the late 1970s, chemical transmission from autonomic nerves to their peripheral effector tissues had been thought to be mediated by noradrenaline or acetylcholine in general. Although most organs are innervated by both sympathetic and parasympathetic nervous systems, blood vessels are innervated by sympathetic nerve fibers, but not appreciably by parasympathetic ones in peripheral systems. Since sympathetic nerve activation after pharmacological blockade by adrenergic receptors still produces residual vasoconstrictions in several vascular beds, nonadrenergic transmitters were indicated to be present in sympathetic nerve terminals (1). On the other hand, parasympathetic nerve-mediated vasodilation was not completely blocked by atropine in doses that block the effects of exogenous acetylcholine in organs such as submandibular salivary gland. Thus, the nonadrenergic, noncholinergic transmission concept has been recognized regarding the autonomic control of both visceral and vascular smooth muscle since Burnstock (2) proposed the concept of purinergic nerves in 1972.
As reviewed by Lundberg (1), sympathetic neuron contains multiple transmitters, mainly noradrenaline, adenosine 5'-triphosphate (ATP), and neuropeptide Y (NPY). It is clear that these three transmitters have distinct differences regarding the time span of action; i.e., ATP acts in milliseconds, noradrenaline in seconds, and NPY in minutes, depending both on receptor 2nd-messenger characteristics and rate of transmitter removal from the sites of action, suggesting that each transmitter has a different role in neurovascular transmission. Noradrenaline is stored in both small and large densecored vesicles via a reserpine-sensitive uptake. After release, noradrenaline activates a variety of postjunctional a -and b-adrenoceptors, which are linked to inositol-1,4,5-triphosphate or cyclic AMP (cAMP) formation, and prejunctional a 2 -adrenoceptors, which inhibit Ca 2+ fluxes, thus reducing further release. It has been reported that ATP is co-stored and co-released with catecholamines from adrenal chromaffin cell granules (3). It has been also reported that ATP is contained together with noradrenaline in sympathetic nerve terminal vesicles (4, 5), suggesting that ATP was released together with noradrenaline from sympathetic nerves (6). By electrophysiological analysis of excitatory junctional potentials (EJPs) in smooth muscle cells of the vas deferens, the release of neuronal ATP could be analyzed pharmacologically. ATP acts on rapid ionotropic P2X receptors, leading to Ca 2+ influx, depolarization, and contraction of smooth muscle (in blood vessels and vas deferens) (7, 8) .
NPY is a 36-amino-acid peptide and the neuronal counterpart to the peptide YY, which is mainly present in intestinal endocrine cells (9). Lundberg et al. (10, 11) predicted NPY may be in a subpopulation of sympathetic neurons containing noradrenaline. NPY is synthesized in the cell body as the precursor, stored in large dense-cored vesicles, and axonally transported to terminal regions. Released NPY may either activate postjunctional receptors (mainly Y 1 type), leading to contraction of vascular smooth muscle (via Ca 2+ mobilization and cAMP inhibition), or prejunctional Y 2 receptors, inhibiting transmitter release (1).
Cannula inserting method for isolated blood vessel preparations
In 1983, Hongo and Chiba (12) developed a method for measuring the vascular responsiveness of relatively larger arteries of dogs. The vessel preparation was intraluminally perfused with a constant flow rate at 37°C. The basal perfusion pressure was within 30 -80 mmHg. Using the cannula inserting method, which was modified by Tsuji and Chiba (13) in 1984, periarterial nerve electrical stimulation (PNS) was performed with various changes in pulse duration, intensity, and frequencies in the canine isolated mesenteric artery (14) .
In this review, we tried to analyze pharmacologically responses to PNS in isolated canine arteries, especially using the isolated, perfused splenic arterial preparation.
Pharmacological analysis of vasoconstrictor responses to PNS

3-1. Effects of adrenergic and purinergic inhibitors on PNS-induced vascular constrictions
In 1984, Chiba and Tsukada (14) reported that PNSinduced vasoconstrictions were blocked by tetrodotoxin (TTX), but not completely by prazosin, using the perfusion technique for canine isolated mesenteric arteries. It was concluded that PNS is useful for investigating the relationship between sympathetic nerve excitation and vascular reactivity in the perfused artery (14).
In canine isolated splenic arterial preparations, it was reported by Ren et al. (15) in 1994 that 1) phentolamine, an a-adrenoceptor antagonist enhanced PNS-induced constriction at a low frequency of 1 Hz but inhibited that at a high frequency of 10 Hz, and 2) suramin and a,bmethylene ATP (ab-m ATP), P 2 purinoceptor antagonists, inhibited PNS-induced constrictions at 1 Hz, but did not change those at 10 Hz, indicating that PNS induces P 2 purinoceptor-mediated responses at a low frequency, but induces a -adrenoceptor-mediated ones mainly at a high frequency.
In 1997, it was also demonstrated that suramin inhibited PNS-induced vasoconstrictions at 5 Hz and lower frequencies, while it did not reduce the responses elicited at high frequencies of 10 and 15 Hz in the canine isolated intermediate auricular artery. Suramin-resistant vasoconstrictor responses were abolished by additional perfusion with phentolamine as shown in Fig. 1 (16) .
From these results, we considered that the co-transmission of noradrenaline and ATP exists at sympathetic nerve terminals even in the canine splenic and intermediate auricular arteries, and that purinergic transmission is mainly involved in the vasoconstrictor responses to low-frequency nerve stimulation (15, 16).
3-2. Biphasic neurogenic vasoconstrictions
Previously, biphasic neurogenic contractions have been observed in the rabbit central ear artery (17), the dog mesenteric artery (18), the largest rami caecales of the rabbit ileocolic artery (19), and the rat mesenteric artery (20). Thus, it has been proposed that the early phase is mainly purinergic and the later phase is noradrenergic.
Recently, Yang and Chiba (21) demonstrated PNSinduced biphasic vasoconstrictor responses, which were consistently induced with conditions of 30-s trains of pulses at 10-V amplitude, 1-ms duration in a frequencyrelated manner in canine isolated, perfused splenic arterial preparations by use of the cannula inserting method. As shown in Fig. 2A , biphasic responses were introduced by PNS even at a range of 1 to 10 Hz when it was continuously stimulated for a long period such as over 30 s. On the other hand, a small number of pulses under 10 usually induced a monophasic vasoconstriction to PNS as shown in Fig. 2B . PNS conditions to obtain such a monophasic response, which is almost purinergic, were previously described in canine splenic arterial preparations (22, 23).
3-3. Effects of adrenergic and purinergic antagonists on PNS-induced biphasic responses
As shown in Fig. 3 , after treatment with prazosin, an a 1 -adrenoceptor antagonist, the 2nd peaked responses were strongly inhibited, indicating that the 2nd peak of the response is mainly as an adrenergic component. After the additional treatment with ab-m ATP, a P2X purinoceptor desensitizer, PNS-induced vasoconstrictions were almost abolished at any of the frequencies used, indicating that the 1st peak of the response is a mostly purinergic component (21).
3-4. Effects of reserpine on PNS-induced biphasic responses
In reserpinized canine splenic arteries, PNS introduced clear 1st peaked but no 2nd peaked responses, especially at a low frequency (24). As shown in Fig. 4 , at low frequencies of stimulation (1 and 4 Hz), the 2nd peaked vasoconstrictions were markedly reduced, whereas the 1st peaked responses were not significantly altered in the reserpinized vessels. At a high frequency of stimulation (10 Hz), both 1st and 2nd peaked responses were still identified, although the magnitude of both peaked responses was significantly decreased, suggesting that any peaked responses contain adrenergic components at a high frequency stimulation. All vasoconstrictor responses after reserpine treatment were not significantly influenced by the treatment with prazosin, but eliminated by a subsequent administration of abm ATP. Therefore, it has been concluded that the PNSinduced adrenergic component is abolished but the purinergic one is not modified by reserpine treatment (24).
Reserpine has been reported to deplete 95% or more of noradrenaline from the postganglionic sympathetic neurons (25, 26). On the other hand, the release of ATP from the sympathetically innervated tissues is not affected by reserpine treatment (27 -29). It has been known that reserpine acts primarily to block the transport of noradrenaline from the cytoplasmic pool to the intragranular pool, leading to a depletion of noradrenaline content from nerve terminals (30, 31). Tyramine is recognized to produce its sympathomimetic action indirectly, via a displacement of noradrenaline from the cytoplasmic pool (31). It is generally accepted that the intragranular pool is a functional and available noradrenaline storage site that is more readily released by nerve impulses. Those conclusions are supported by observations from isolated atria of reserpine-treated guinea pig, rabbits, and cats that refilling the noradrenaline stores restored the responses of the atrial pacemaker to tyramine but not to sympathetic nerve stimulation (32 -34) . In contrast to those reports, Yang and Chiba (24) found that not only tyramine-induced but also nerve stimulation-induced adrenergic responses were consistently restored after replenishment with noradrenaline, as demonstrated previously in the guinea pig vas deferens (35) and cat nictitating membrane (36) . These different results might be due to organ differences.
3-5. Effects of guanethidine on PNS-induced biphasic responses
Guanethidine, at a low concentration (0.1 mM) did not modify the 1st peaked response but markedly inhibited the 2nd one at lower frequencies (1 -2 Hz) (37) . On the other hand, it slightly but significantly inhibited the biphasic responses at higher frequencies (6 -10 Hz). It might suggest that the 1st peaked response contains an adrenergic component at higher frequency stimulation. A high dose of guanethidine almost completely inhibited the 2nd peaked response at any frequencies, but did not completely inhibit the 1st peaked one as shown in Fig. 5 . Thus, it is suggested that guanethidine may exert a dominant inhibitory effect on adrenergic rather than on purinergic components, which in turn guanethidinesensitive mechanisms contribute to determine noradrenaline release rather than ATP release from neuronal vesicles (37).
3-6. Effects of imipramine and rauwolscine on PNSinduced biphasic responses
The 2nd peaked response was significantly enhanced by treatment with imipramine, an uptake inhibitor, but the 1st one was not influenced by it (38) . As shown in Fig. 6B , imipramine potentiates the 2nd peaked response at 1 Hz, but it does not significantly modify the 1st peaked one. As shown in Fig. 6C , prazosin abolishes the imipramine-induced amplification and the 2nd peaked response has mostly disappeared in the same preparation. The response remaining after prazosin is completely blocked by a subsequent application of abm ATP as shown in Fig. 6D . Thus, it is clear that imipramine potentiates the adrenergic component to PNS, but does not influence the purinergic one (38) .
The treatment with rauwolscine, an a 2 -adrenoceptor antagonist, significantly potentiated PNS-induced double peaked responses; i.e., both 1st and 2nd peaked responses (39) . Figure 7 shows that PNS-induced responses are enhanced by treatment with 1 mM rauwolscine. As shown in Fig. 7C , 0.1 mM prazosin abolishes the rauwolscine-induced effects, and moreover, the 2nd peaked response is additionally inhibited. The responses remaining after prazosin are abolished by a subsequent treatment with 1 m M ab-m ATP as shown in Fig. 7D . After the a 2 -adrenoceptor blockade by rauwolscine, at low frequencies, the response to PNS was consistently potentiated and the enhanced responses were mostly inhibited by a 1 -adrenoceptor blockade. Therefore, even at low frequencies there may exist the a 1 -adrenergic component that may be distinguished by the inhibition of a 2 -adrenoceptors, because the enhanced responses were mostly suppressed by prazosin treatment. It may indicate that tonically adrenergic a 2 mechanisms may exist at the presynaptic level. Thus, it is suggested that every phase of vasoconstriction in any frequency may involve an adrenergic and / or purinergic component; i.e., adrenergic-purinergic interactions may cause a variety of vasoconstrictions (39) .
3-7. Effects of w-conotoxin (w-CTX) on PNSinduced biphasic responses
The depolarization-induced release of neurotransmitters is dependent upon a prejunctional influx of extracellular calcium ions through voltage-gated calcium channels (VGCCs) (40) . N-Type VGCCs have been shown to play a key role in triggering neurotransmitter release from sympathetic nerve terminals (41) . In 1994, Ren et al. (42) reported that PNS-induced vasoconstrictor responses were inhibited by w-CTX in isolated canine splenic arteries. However, they did not confirm effects of w-CTX on the biphasic response to PNS. Recently, Yang and Chiba (43) demonstrated that w-CTX (1 -30 nM) produced similar inhibitory effects on either the 1st or 2nd peaked response in a dose-related manner. Figure 8A shows that w-CTX parallel inhibits the PNS-induced biphasic response (44) . w-CTX at 30 nM almost completely inhibited the biphasic responses at all the frequencies of stimulation, but did not affect the vasoconstrictor responses to exogenous applied ATP and noradrenaline. Diltiazem, an L-type VGCC antagonist significantly inhibited the responses to exogenous ATP and noradrenaline, although it inhibited the responses to PNS. It was indicated that w-CTX selectively acts prejunctionally to inhibit the release of transmitters from sympathetic nerve terminals, and w-CTX-sensitive calcium channels may produce a parallel controlling of purinergic and adrenergic compounds of sympathetic cotransmission (43, 44) .
3-8. Effects of TTX on PNS-induced biphasic responses
It is well known that TTX, a selective sodium channel inhibitor, abolishes the nerve action potential and, thus, blocks the release of neurotransmitters (45 -47) . Many functional experiments have also demonstrated that TTX consistently abolishes the biphasic vasoconstrictor response to PNS, in which ATP and noradrenaline act as cotransmitters (17 -19). Even in our experiments, PNS-induced responses were abolished by a relatively large concentration of TTX in the canine isolated splenic 8 . Effects of w -conotoxin GVIA (w -CTX) (A), tetrodotoxin (TTX) (B), and prolonged cold storage (7 days at 4°C) (C) on the double-peaked vasoconstrictor responses to a train of 30 pulses at 1 Hz of stimulation in the canine splenic arteries. **P<0.01, as compared with the control group; ## P<0.01, as compared with the fresh arteries. Symbols represent the mean ± S.E.M., n = 6. Modified from Ref. 44. artery (42, 44, 48) . However, it was also shown that a submaximal concentration of a relatively small dose of 3 nM TTX had no effect on the 1st peaked response, but almost completely inhibited the 2nd peaked one at low frequencies of PNS (1 -3 Hz), although at higher frequencies, the biphasic responses were almost equally inhibited by 50% by 3 nM TTX. A large dose of TTX abolished PNS-induced responses. Thus, in conclusion, progressive inhibition of sodium channels by increasing the concentration of TTX may exert a more preferential inhibition on adrenergic rather than purinergic components, suggesting that TTX-sensitive sodium channels may have a more important role in determining the adrenergic rather than purinergic transmission of sympathetic nerves (48) . As shown in Fig. 8B, 3 nM TTX selectively inhibits the 2nd peaked response to PNS (44) .
3-9. Effects of prolonged cold storage on PNSinduced biphasic responses
After cold storage (4 -7 days at 4°C) of isolated canine splenic arteries, the 1st peaked response was markedly decreased, whereas the 2nd one was not significantly modified as shown in Fig. 8C (44) . In this condition, the vasoconstrictor responses to exogenous noradrenaline and ATP were not significantly modified by the prolonged cold storage, indicating that postsynaptic processes of adrenergic and purinergic components might not be modified functionally (49, 50) . It is concluded that the prolonged cold storage of vessels may preferentially depress the co-transmission of purinergic component, whereas the adrenergic component might still largely remain in the canine isolated splenic artery (44, 49, 50) . The precise mechanism needs to be investigated in the future.
3-10. Effects of angiotensin II on PNS-induced biphasic responses
Angiotensin II at a concentration of 0.1 nM did not affect the basal vascular tone and vasoconstrictor responses to exogenously administered noradrenaline and ATP, but it markedly potentiated the biphasic responses to PNS (51) . The potentiating effect of angiotensin II was inhibited by KRH-594, a selective AT 1 -receptor antagonist, but not influenced by PD123319, a selective AT 2 -receptor antagonist. Moreover, treatment with enalapril, an angiotensin-converting enzyme inhibitor significantly reduced PNS-induced biphasic responses (J. Komiyama et al. unpublished data). It was indicated that angiotensin II potentiates sympathetic purinergic and adrenergic vasoconstrictions through the prejunctional AT 1 receptor subtype in the canine splenic artery (51).
3-11. Effects of NPY on PNS-induced biphasic responses
It has been recognized that NPY is a 36 amino-acid peptide and one of the important co-transmitters in sympathetic nerve terminals (1). In the periphery, NPY is stored in large dense-cored secretory vesicles, partially different from the vesicular storage of noradrenaline in sympathetic nerve fibers and axonally transported to terminal regions (52, 53) .
In canine isolated splenic arteries, NPY did not induce a consistent vasoconstriction by itself. When NPY (0.01 and 0.1 m M) was intraluminally given into the isolated splenic artery, there was no direct constriction in about half of the preparations used (54) . In the remaining preparations, NPY produced only a slight vasoconstriction.
After incubation of NPY for 30 min, both phases of the response to PNS were inhibited in parallel, indicating that NPY modifies vascular responses to PNS. Recently, several non-peptide antagonists with high subtype selectivity for NPY receptors have been introduced as reviewed by Malmström (55) . More recently, we have already published a review article on the role of NPY in functional neurovascular transmission in the canine splenic artery (56) . Therefore, it is briefly described here, using the recent publications from our laboratories (57 -63) . We showed that NPY(13 -36), a selective NPY Y 2 -receptor agonist led to a reduction of biphasic vasoconstrictions without affecting responses to exogenous noradrenaline and ATP (57) . The inhibition by NPY(13 -36) was effectively prevented by BIIE0246, a selective NPY Y 2 -receptor antagonist, indicating that the effect of the NPY analogue to inhibit neuronally evoked vasoconstrictions is due to its action at a prejunctional site via a putative NPY Y 2 receptor subtype.
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] neuropeptide Y (LP-NPY), a selective NPY Y 1 -agonist, induced an enhancement of vasoconstrictor response to PNS; i.e., the 1st peaked response was slightly but the 2nd peaked one was markedly potentiated in isolated splenic arteries (58) . It was also confirmed that the potentiation of LP-NPY was inhibited by BIBP3226, a NPY Y 1 -receptor antagonist (58 -60) . It seems that the activation of NPY Y 1 receptors by LP-NPY may selectively modulate the adrenergic rather than the purinergic transmission of sympathetic cotransmission in the canine splenic artery (58 -60) .
It was reported that PNS-induced 2nd peaked response was significantly inhibited by either chloroethylclonidine (CEC), an a 1B -adrenoceptor antagonist or BMY7378, an a 1D -adrenoceptor antagonist, but not by WB4101, an a 1A -adrenoceptor antagonist (61, 62) . On the other hand, exogenous noradrenaline-induced responses were blocked by WB4101, but not by either CEC or BMY7378, indicating the junctional adrenoceptor subtype is a 1B and / or a 1D , although the extrajunctional subtype is a 1A . It is also demonstrated that the potentiation of PNS-induced responses by LP-NPY was observed even after treatment with BMY7378, but not by CEC, indicating that the postjunctional a 1B -adrenoceptor subtype is likely coupled to NPY Y 1 -receptors responsible for cooperation of the sympathetic adrenergic and NPYergic transmission in the canine splenic artery (63).
Conclusion
On the basis of our results and references, which our laboratories have reported for canine splenic arteries over the last 5 years, a schematic illustration of effects of various drugs and cold storage on PNS-induced releasing mechanism for ATP and noradrenaline is shown in Fig. 9 .
Furthermore, Fig. 10 shows a schematic illustration of the effects of NPY-related compounds on the PNSinduced releasing mechanism of noradrenaline and NPY and on a 1 -adrenoceptor subtypes of neuroeffector junctional and extrajunctional areas in canine splenic arterial preparations. 
